Strategy Change and Platform Validation
Our analysts recently identified a stock that has the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 choice. Tap here.
-
Management has planned the business to focus exclusively on two high-impact markets—chemicals and ag-chemicals—where its ChemPass AI engine provides a distinct competitive advantage.
-
The company’s mission is now focused on designing novel, small molecules that have the potential to be easily synthesized and better aligned with target product profiles.
-
A key pillar of the strategy is a collaboration with Google to integrate AI agents into the ChemPass platform, which aims to automate the extraction of information from scientific literature to create proprietary datasets.
-
The business model uses a dual approach: establishing strategic partnerships to reduce financial risk and developing an internal pipeline to secure better commercial terms later.
-
The Pharma activities, launched only at the beginning of 2025, quickly grew to four ongoing collaborations, showing the strong validation of the AI-driven discovery platform market.
-
Management believes that success in one sector, such as agriculture, serves as a proof of concept that accelerates collaboration and trust with partners in the pharmaceutical industry.
Pipeline Milestones and Partnership Trajectory
-
The company expects to advance its existing chemical and ag-chemical pipelines to reach value creation milestones throughout the remainder of 2026.
-
Management is actively exploring opportunities to establish a new drug development pipeline to complement its current collaborative projects.
-
In the agricultural sector, the company expects that its in-house Septoria fungicide program will continue to show improved values through AI-driven design.
-
Castor cultivation in Brazil is planned for commercial launch, with seed sales expected to begin in the 2027 growing season.
-
Strategic talks are continuing with ‘big pharma’ and other tech giants such as Google, although executives note that strategic deals related to pharma equity could take several phases to materialize.
Operational Restructuring and Portfolio Planning
One stock. Nvidia-grade power. 30M+ investors hope Moby gets it first. Get a choice. Tap here.
-
Evogene ended its collaboration with Bayer research on herbicide development due to problems with the biology of the target protein, although the partnership confirmed the company’s ability to do so.
-
The company is significantly reducing or terminating non-core subsidiaries, including Lavie Bio and Biomica, to focus resources on the ChemPass AI platform.
-
The February 2026 warrant settlement resulted in net cash of $3.4 million but also contributed to non-cash financing costs due to accounting revisions.
-
The company reported a consolidated cash position of approximately $13.1 million as of March 31, 2026, with additional cash inflows expected from dividend distributions.
